Use of noninvasive fibrosis calculators in an urban diabetes center suggests a large burden of undetected advanced liver disease

Abstract Background Metabolic dysfunction associated steatotic liver disease (MASLD) is prevalent in up to 60% of patients with type 2 diabetes mellitus (T2DM). T2DM accelerates the risk of hepatic fibrosis and hepatocellular carcinoma in patients with MASLD. Our goal in this study was to identify p...

Descripción completa

Detalles Bibliográficos

Autores principales:	Ahmed Ebeid, Fatma Mokhtar, Valeria Martinez-Lebron, Susie Park, Seta Degann, Jeremy Payano, Zahid Vahora, Stephen Gray, Lynt Johnson, Diala El-Maouche, Ameer Abutaleb
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	BMC 2025-02-01
Colección:	BMC Endocrine Disorders
Materias:	Metabolic dysfunction associated steatotic liver disease (MASLD) MASH Fibrosis scoring systems Non-invasive tests Advanced liver fibrosis
Acceso en línea:	https://doi.org/10.1186/s12902-025-01881-9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!